CCND1 and non-small cell lung carcinoma: For instance, PanDrugs prescribes Palbociclib (Additional file 1: Figure S10A), a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6, to treat this NSCLC patient as a result of the following evidence: (1) CDK6 is a direct target; (2) CCND1, CDKN2A, and CDKN2B are biomarkers; and (iii) CDK4 is a downstream pathway member gene.